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Abstract
Human immunodeficiency virus 1 (HIV-1) viral protein R (Vpr) has been shown to induce host cell death by increasing the
permeability of mitochondrial outer membrane (MOM). The mechanism underlying the damage to the mitochondria by Vpr,
however, is not clearly illustrated. In this study, Vpr that is introduced, via transient transfection or lentivirus infection, into
the human embryonic kidney cell line HEK293, human CD4
+ T lymphoblast cell line SupT1, or human primary CD4
+ T cells
serves as the model system to study the molecular mechanism of Vpr-mediated HIV-1 pathogenesis. The results show that
Vpr injures MOM and causes a loss in membrane potential (MMP) by posttranscriptionally reducing the expression of
mitofusin 2 (Mfn2) via VprBP-DDB1-CUL4A ubiquitin ligase complex, gradually weakening MOM, and increasing
mitochondrial deformation. Vpr also markedly decreases cytoplasmic levels of dynamin-related protein 1 (DRP1) and
increases bulging in mitochondria-associated membranes (MAM), the specific regions of endoplasmic reticulum (ER) which
form physical contacts with the mitochondria. Overexpression of Mfn2 and DRP1 significantly decreased the loss of MMP
and apoptotic cell death caused by Vpr. Furthermore, by employing time-lapse confocal fluorescence microscopy, we
identify the transport of Vpr protein from the ER, via MAM to the mitochondria. Taken together, our results suggest that
Vpr-mediated cellular damage may occur on an alternative protein transport pathway from the ER, via MAM to the
mitochondria, which are modulated by Mfn2 and DRP1.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) infection is
characterized by a severe decrease in the number of CD4
+ T
lymphocytes, and several mechanisms have been proposed to
explain it. One major factor associated with the reduction in CD4
+
T lymphocytes is HIV-1 viral protein R (Vpr), a small 96-amino
acid protein, that mediates cell cycle arrest, DNA damage, and
apoptosis [1,2,3,4,5,6,7].
Several lines of evidence have suggested that the killing of cells
by Vpr might be the result of targeting mitochondria through a
direct interaction with adenine nucleotide translocator (ANT) on
the mitochondrial inner membrane to permeabilize mitochondrial
membrane and release cytochrome c [7,8,9,10,11]. However,
silencing of ANT had no effect on Vpr-induced apoptosis whereas
knockdown of Bax suppressed it [12]. In addition, Vpr was shown
to form an ion channel in vitro via its hydrophobic segment (amino
acids 55–83) [8,11] penetrating phospholipid bilayers [8,11,13].
Moreover, the configuration of Vpr C-terminal transmembrane
domain (TMD) is similar to that of certain viral proteins, such as
Myxoma virus M11L protein, vaccinia virus F1L protein, Epstein-
Barr virus BHRF-1 protein and hepatitis C virus core protein. The
C-terminal hydrophobic segments of these viral proteins contain
mitochondrial targeting sequences (MTS), which are homologous
to tail-anchored proteins [11,13,14,15,16,17,18]. The major
feature of these proteins is that they all have one membrane
anchor at the C-terminus, comprising one helical hydrophobic
domain of 12 to 24 amino acids followed by positively charged
amino acids [19,20,21]. However, details of the mechanism
underlying the transport of Vpr to mitochondria and the
deteriorating effect of Vpr on mitochondria have yet to be
determined.
In this study, we demonstrate that Vpr is present on the
endoplasmic reticulum (ER), mitochondria-associated membranes
(MAM), and the mitochondrial outer membrane (MOM), possibly
via the integration of its C-terminal transmembrane domain. Vpr
integration on mitochondria could lead to mitochondrial frag-
mentation and disruption of the integrity of the MOM, which
might result in the discharge of mitochondrial membrane potential
(MMP). Moreover, we found that this effect could be due to a Vpr-
related reduction in the protein levels of mitochondrial fusion
protein, mitofusin 2 (Mfn2) via VprBP-DDB1-CUL4A ubiquitin
ligase complex. However, transport of Vpr to the mitochondria is
independent of the translocase of mitochondrial outer membrane
(TOM). Our results suggest that Vpr could be transported to
mitochondria by an alternative protein transport pathway, from
the ER via the MAM, requiring at least three proteins, dynamin-
related protein 1 (DRP1), Mfn2, and ATPase family, AAA domain
containing 3A (ATAD3A) [22]. Interruption of this putative
pathway by Vpr, by means such as reducing the expression of
Mfn2 and DRP1, has a profound influence on the morphology
and function of the mitochondria.
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Vpr is integrated in the mitochondrial outer membrane
(MOM) by the C-terminal transmembrane domain,
independent of the translocase of mitochondrial outer
membrane (TOM)
Sequence analysis revealed that Vpr had a C-terminal
transmembrane domain (TMD) followed by a positively charged
amino acid, resembling the classical tail-anchored protein of ER
and MOM [13,16,19,21]. We therefore subcloned the C-terminal
fragment (amino acid residues 52–96) of Vpr into a mammalian
expression vector containing green fluorescent protein (GFP) to
determine the localization of Vpr by subcellular fractionation and
Western blotting. As shown in Figure 1A, Vpr-GFP proteins were
detected in the mitochondria and in the cytosol. Fluorescence
confocal microscopic images further confirmed that both Vpr- and
Vpr52–96-GFP were present in the mitochondria (Fig. 1B). To
identify the type of association, the mitochondria from Vpr-GFP
expressing cells was isolated and treated with Na2CO3 to separate
associated proteins from integral membrane proteins. As antici-
pated, Vpr-GFP and Vpr52–96-GFP were both identified in the
pellet, containing membrane proteins, suggesting that Vpr is an
integral membrane protein of mitochondria (Fig. 1C). To assess
the orientation of Vpr integration, we used two types of constructs,
one containing hemagglutinin at the amino-terminus (N-terminus),
HA-Vpr, and the other containing GFP at the carboxy-terminus
(C-terminus), Vpr-GFP or Vpr52–96-GFP, for a proteinase K
protection assay. The N-terminal HA protein (Fig. 1D), but not
the C-terminal fragment of either Vpr-GFP or Vpr52–96-GFP
(Fig. 1E and 1F), was sensitive to proteinase K, suggesting that the
N-terminus of Vpr was facing the cytosol while the C-terminus was
anchored to the MOM. Previous studies have shown that
importing mitochondrial protein is mediated by a mitochondrial
protein translocation machinery, TOM complex, comprising the
major receptors proteins, Tom20 and Tom22, and the central
channel protein Tom40 [23]. Using Western blotting to examine
mitochondrial content of ectopically expressed Vpr-GFP in
Tom22 knockdown (Tom22
KD) and Tom40
KD cells, we observed
no significant difference in Vpr-GFP expression between
Tom22
KD and the control cells or between Tom40
KD and the
control cells (Fig. 1G). Similarly, silencing of Tom20 did not
influence the mitochondrial import of Vpr (data not shown);
however, mitochondria protein COX IV, which has been known
to be imported into mitochondria via TOM complex, showed a
marked decrease (,0.5-fold) (Fig. 1H and 1I). These results
suggest that the transport of Vpr to mitochondria is TOM-
independent.
Vpr protein is integrated into the endoplasmic
reticulum (ER)
The presence of the C-terminal TMD sequence predicted that
Vpr could be integrated into the ER as well. Using confocal
fluorescence microscopy, we found that both Vpr-GFP and Vpr52–
96-GFP wereindeedlocatedintheER(Fig.2A).Vprwasspecifically
associated with the ER, as shown by Na2CO3 washing of
microsomal fractions (including the ER) to remove non-specific
binding proteins (Fig. 2B). Using protease protection assay and
Western blotting, we also found that Vpr in microsomal fractions
was resistant to trypsin (Fig. 2C), indicating that, similar to what was
observed in the mitochondria, Vpr was an integral protein of the
ER. Furthermore, by employing immunogold transmission electron
microscopy, Vpr proteins were identified on the MOM (Fig. 2D,
arrowhead) and the ER (Fig. 2D, arrows). These results correspond
well with our prior data. As a comparison, no immunogold signal
(detecting Vpr) was detected in cells transfected with vectors only
(data not shown). Statistically, 29.3% of the immunogold particles
(detecting Vpr) were in the cytosol, 30.7% in the mitochondria,
18.7% in the vesicular structures and 9.3% in the ER.
Vpr induces bulging of the mitochondria-associated
membrane (MAM)
Detection of Vpr in both the ER and the mitochondria suggests
that Vpr could be delivered separately to these two organelles
following the synthesis of protein or transferred sequentially from
the ER to the mitochondria [24,25]. It is interesting to note that a
connection between these two organelles and MAM has been
hypothesized as a route of delivery for viral proteins from the ER
to mitochondria, and it is possible that Vpr may be trafficked by
this route. Using Percoll gradient and Western blotting, we found
that Vpr-GFP and Vpr52–96-GFP were distributed in cytosol, ER,
MAM, and purified mitochondria (Fig. 3A, 3B and 3C).
Immunofluorescence confocal microscopic images verify that
Vpr signals were co-localized with the marker signals of ER,
MAM and mitochondria (Fig. 3D and 3E). Moreover, these
images show that Vpr-GFP, and in particular Vpr52–96-GFP, were
located mainly in the bulging ER/MAM, suggesting that
overexpressed Vpr could be accumulated in the MAM, a
prospective docking area for mitochondrial proteins prior to
transportation [22].
To rule out what we observed above was due to GFP fusion,
HA-Vpr expressing cells were fractionated and analyzed by
Western blotting. Consistently, HA-Vpr was distributed in cytosol,
ER, MAM, and purified mitochondria (Fig. 3F). Cell cycle analysis
showed that Vpr-GFP, Vpr52–96-GFP, and HA-Vpr all led to an
increase (relative to the control) in the G2/G1 ratio, which
reflected its G2 arrest activity (Fig. 3G). In comparison, full-length
Vpr was introduced into lentiviral expressing vector to mimic the
function of native Vpr. Cell cycle analysis indicated that Lenti-Vpr
infection caused a profound G2 arrest (Fig. 3G). Based on G2/G1
ratio, Vpr52–96-GFP (1.55) showed a comparable G2 arrest activity
as Lenti-Vpr (1.42). On the other hand, HA-Vpr (1.09) and Vpr-
GFP (0.71) induced lower G2/G1 ratios than Lenti-Vpr.
Vpr expression reduces expression level of mitochondrial
protein Mfn2
Interestingly, following Vpr transfection or Lenti-Vpr infection,
the expression level of Mfn2 was markedly reduced (Fig. 4A and
4B), while that of GRP78 was significantly increased (Fig. 4A).
Vpr, however, did not influence the mRNA levels of GRP78 or
Mfn2 (data not shown), suggesting that the influence of Vpr on
these proteins could be post-transcriptional. It is worth noting that
Vpr caused a loss in mitochondrial membrane potential (MMP)
(Fig. 4C), a phenomenon that could also be induced by Mfn2
silencing (Fig. 4D and 4E). The influence of Vpr on MMP loss was
approximately one third of that caused by Mfn2 silencing
[26,27,28]. In addition, Mfn2 reduction was also observed in
HA-Vpr expressing cells (Fig. 4F).
Vpr protein induces abrasion of MOM and deformation
of mitochondrial cristae
In a recent report we showed that in addition to inter-
mitochondrial fusion, Mfn2 facilitates the fusion of the mitochon-
dria and transport vesicles, which were budding off from the
MAM, in an alternative transport pathway of mitochondrial
proteins. This pathway requires at least three proteins, dynamin-
related protein 1 (DRP1), the ATPase family AAA domain
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GTPases, and ATAD3A is an ATPase. Deficiency in any of the
three enzymes induces mitochondrial deformation, fragmentation,
and cell death. Interestingly, compared with wild-type or GFP
expressing cells (Fig. 5A and 5B), the morphology of the
mitochondria was altered in Vpr-GFP and Vpr52–96-GFP
expressing cells (Fig. 5C and 5D), as demonstrated by transmission
electron microscopy. In these cells, the cristae were swollen,
mitochondrial matrices condensed, and the outer membranes
abraded (Fig. 5E and 5F).
Figure 1. The C-terminal TMD is crucial to the integration of Vpr into MOM. A, The C-terminal TMD is required for the subcellular
distribution of Vpr to mitochondria. B, Using confocal immunofluorescent microscopy, Vpr-GFP was localized on the mitochondria. Mitochondria
were labeled using plasmid encoding mitochondria-targeted Discosoma red fluorescent protein (DsRed-Mito). Yellow fluorescence indicates the
overlapping regions between the Vpr and mitochondria (white arrow). Bar: 10 mm. C, Treatment with 100 mM sodium carbonate (pH11.5) showed
that Vpr and COX IV, as integral proteins of the mitochondrial inner membrane, were resistant to sodium carbonate, while the peripherally associated
matrix protein mtHsp70 was separated in the soluble fraction. All experiments were independently repeated three times. D, Mitochondria isolated
from HA-Vpr expressing cells were treated with proteinase K. The level of HA-Vpr was decreased after proteinase K treatment, indicating that the N-
terminal HA was sensitive to protease. E, The C-terminal GFP fragment of the Vpr-GFP was resistant to proteinase K, indicating that the C-terminus of
Vpr was protected. F, Resistance of the C-terminal GFP fragment of Vpr52–96-GFP to proteinase K treatment indicated that C-terminal GFP fragments
were oriented toward the mitochondria. G, Following silencing of Tom22 or Tom40, cells were transfected with Vpr-GFP for 48 hours. Although
expression of Tom22 or Tom40 was significantly reduced in gene silencing cells, expression of Vpr-GFP was not affected. H, The mitochondrial level of
Vpr was not affected either in Tom22
KD or Tom40
KD cells as shown by Western blotting. I, The relative expression of mitochondrial Vpr-GFP in
Tom22
KD and Tom40
KD cells was similar to that in control cells, although the mitochondrial protein COX IV was markedly reduced. The results are
shown as the means 6 S.D. of three independent experiments. ***The difference of relative expression is statistically significant (p,0.001) between
the control and Tom22
KD cells or that and Tom40
KD cells.
doi:10.1371/journal.pone.0033657.g001
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KD) expression induces the
accumulation of Vpr in the MAM whereas actopic
expression of Vpr induces nuclear translocation of DRP1
As noted above that ATAD3A, DRP1 and Mfn2 are involved
in the importation of mitochondrial protein from the MAM, a
prospective docking area prior to shipment [22]. Furthermore,
Vpr could reduce Mfn2 expression. Interestingly, the knockdown
of DRP1 (DRP1
KD) (Fig. 6A), an up-stream GTPase which was
essential for fission of transport vesicles from the MAM, altered
the distribution of Vpr in the ER, MAM, and mitochondria: a
reduction in the ER and mitochondria, but an increase in the
MAM (Fig. 6B). Moreover, the ectopic expression of Vpr or
Vpr52–96 increased the levels of nuclear DRP1, in particular the
phosphorylated DRP1 (pDRP1) as determined by Western
blotting (Fig. 6C). These results were confirmed by confocal
immunofluorescence microscopy, in which Vpr52–96 increased
the nuclear levels of Vpr and DRP1 (Fig. 6D). In some cells,
DRP1 was co-localized with Vpr at the nucleolus. An increase in
nuclear DRP1 was correlated with the expression of Vpr or
Vpr52–96 in the cells. The differences were statistically significant
(Fig. 6E). Consistently, HA-Vpr changed the distribution of
DRP1 (Fig. 6F) as Vpr-GFP or Vpr52–96-GFP did. Knockdown of
Mfn2 (Mfn2
KD) or ATAD3A (ATAD3A
KD) increased cytosolic
Vpr levels, and reduced mitochondrial Vpr levels (Fig. 6G and
6H), which could be resulted from the accumulation of transport
vesicles.
Vpr-containing transport vesicles are formed from the
ER/MAM and these vesicles fuse into mitochondria as
determined by the time-lapse confocal fluorescence
microscopy
To record the formation of Vpr-containing transport vesicles
from the ER/MAM and the fusion of these vesicles into the
mitochondria in real time, we employed time-lapse confocal
fluorescence microscopy. As shown in the time series of Fig. 7A,
some of Vpr signals (green fluorescence) were overlapped with
those of the ER/MAM (red fluorescence). The overlapped areas
appeared as yellow fluorescence. Some other Vpr signals were
found to be budding off from the side of the ER/MAM, and
emerged as small green fluorescent vesicles (T=14 s–28 s,
Fig. 7A). Immediately, the Vpr-containing vesicles (green fluores-
cence, Fig. 7B) were found to approach a mitochondrion (T=28 s,
red fluorescence, Fig. 7B) and then fuse into the mitochondrion
(T=56 s, Fig. 7B). The new fusion site appeared as yellow
Figure 2. Transport of Vpr to the ER. A, Confocal immunofluorescent microscopy localized Vpr at the ER. ER was labeled using plasmid encoding
ER-targeted Discosoma red fluorescent protein (DsRed-ER). Yellow fluorescence indicates the overlapped regions between Vpr and ER (white arrow).
Bar: 10 mm. B, Treatment with 100 mM sodium carbonate confirmed that Vpr and the ER integral protein Calnexin were present in the alkaline-
resistant fraction. C, Isolated microsomal fractions treated with trypsin indicate that Vpr inserted into the ER by the C-terminal TMD. D, Using
immunogold electron microscopy, Vpr particles (15 nm) were shown to be located on the membrane of mitochondria (arrowhead) and ER (arrow).
These results are representative of three independent experiments.
doi:10.1371/journal.pone.0033657.g002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33657Figure 3. Vpr is presented in the MAM. A, Using Percoll self-generating gradient fractionation, Vpr-GFP was localized in the ER, MAM, and
mitochondria. Cyto: cytosolic fraction, LM: microsomal fraction, Mito: mitochondrial fraction. B, Likewise, Vpr52–96-GFP was located in the ER, MAM,
and mitochondria. C, Relative expression levels of Vpr-GFP and Vpr52–96-GFP in different subcellular fractions are similar. D, Immunofluorescent
confocal microscopy showed that Vpr was co-localized with the MAM marker, PSS-1 protein. Bulged MAM became evident in Vpr52–96-GFP expressing
cells. Yellow fluorescence (white arrow) indicates an overlap between Vpr (green fluorescence) and MAM (red fluorescence). Bar: 10 mm. E,
Colocalization of Vpr52–96-GFP or Vpr-GFP with the marker of ER, MAM and mitochondria was assessed based on confocal images, and 100–120 cells
were scored in three independent experiments. The results showed that both proteins were present in the three organelles. F, HEK293 cells were
transfected with the plasmid encoding HA-Vpr for 48 hours. Cells were harvested and fractionated on a self-generated Percoll gradient. HA-Vpr was
localized in the ER, MAM, and mitochondria. Cyto: cytosolic fraction, LM: microsomal fraction, Mito: mitochondrial fraction. G, HEK293 cells were
either transfected with the plasmid encoding Vpr-GFP, Vpr52–96-GFP, or HA-Vpr for 48 hours, or infected with Lenti-Vpr (48 and 72 hours). Cells were
harvested and cell cycle was analyzed by flow cytometry. Vpr-induced G2 arrest was observed in Vpr-expressing cells.
doi:10.1371/journal.pone.0033657.g003
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33657Figure 4. Vpr influences the expression level of GRP78 and Mfn2 proteins. A, At 48 hours post-transfection, expression of Vpr-GFP or Vpr52–
96-GFP up-regulated GRP78 level, but reduced Mfn2 level in HEK293 cells. B, Vpr-related decrease in the expression of Mfn2 was time-dependent after
Lenti-Vpr infection. C, Vpr-related loss of mitochondrial membrane potential (MMP) was also time-dependent, indicating that the effect of Vpr on
MMP change was gradual, not immediate. D, Infection of HEK293 cells with lentivirus carrying siRNA to Mfn2 markedly reduced protein levels
48 hours after viral treatment. E, Similar to that mediated by Vpr, the Mfn2 silencing-induced loss of MMP was time-dependent. Results are the means
6 S.D. of three independent experiments. For panels C and E,*( p,0.05) and *** (p,0.001) indicate significantly different from the control. F,
HEK293 cells were transfected with the plasmid encoding HA-Vpr for 48 hours. Cells were harvested and analyzed by Western blotting. The
expression of Mfn2 was reduced in HA-Vpr expressing cells.
doi:10.1371/journal.pone.0033657.g004
Figure 5. Vpr protein influences the morphology of mitochondria and integrity of MOM. A, Electron microscopic analysis of HEK293 cells
showed that mitochondria were intact with a double-layer membrane and regular arrangement of cristae. Bar: 200 nm. B, Similar to wild-type cells,
expression of GFP did not influence the morphology of the mitochondria. Bar: 200 nm. C, Following Vpr-GFP expression, marked changes in the
architectureofthecristaewasobserved.Vprledtoswollencristae,condensedmatrix(arrowhead)andgraduallydisappearanceofoutermembrane(arrow).
Bar: 200 nm. D, The same phenomenon was observed with Vpr52–96-GFPexpressing cells. Mitochondria were condensed with swollen cristae. Bar: 200 nm.
E, Based on TEM images, Vpr induced mitochondrial fragmentation and the length of mitochondria was evidently shorter. Twenty five cells were scored in
three independent experiments with means 6 S.D. F, Vpr also resulted in the condensation of mitochondria. For panels E and F, 25 cells were scored in
three independent experiments with means 6 S.D. *** indicates statistically significant difference (p,0.001) between the control and Vpr-expressing cells.
doi:10.1371/journal.pone.0033657.g005
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Vpr could be budding off from ER/MAM and formed within a
transport vesicle, which moved to the neighborhood of a
mitochondrion and fused into the organelle. The rate of Vpr
formation from the MAM was faster than that of transport vesicle
fusion into the mitochondrion.
Figure 6. Knockdown of DRP1 (DRP1
KD) expression induces the accumulation of Vpr in the MAM. Ectopic expression of Vpr, on the
other hand, induces nuclear translocation of DRP1. A, Treatment with siRNA for 48 hours reduced the expression of DRP1 by approximately
80%. B, In DRP1
KD cells, protein levels of Vpr, Calnexin and GRP78 were increased in the MAM, while those of Vpr were decreased in the ER and
mitochondria, indicating that the knockdown of DRP1 expression induced the accumulation of Vpr in the MAM. The results are representative of two
independent experiments. C, The presence of Vpr or Vpr52–96 increased the levels of DRP1, in particular phosphorylated DRP1 (pDRP1), in the nucleus,
as determined by Western blotting. These results are representative of two independent experiments. D, As shown by confocal immunofluorescence
microscopy, ectopic expression of Vpr52–96 increased nuclear levels of Vpr and DRP1 (arrows with white margin). In some cells, both Vpr and DRP1
were co-localized in the nucleolus (white arrows). Bar: 10 mm. E, The increase of nuclear DRP1 in Vpr- or Vpr52–96-expressing cells. Fifty cells were
scored in three independent experiments with means 6 S.D. * (p,0.05) and ** (p,0.01) indicate significantly different from the control. F, HA-Vpr
increased nuclear levels of DRP1. G, and H, The effect of gene knockdown of Mfn2 (Mfn2
KD) or ATAD3A (ATAD3A
KD) on the organelle distribution of
Vpr was determined by Western blotting. Vpr level was increased in the cytosolic fractions, but it was reduced in the mitochondrial fractions in both
Mfn2
KD and ATAD3A
KD cells. Band intensities were calculated using Image J. Relative intensities are shown at the bottom of each panel.
doi:10.1371/journal.pone.0033657.g006
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HEK293 and CD4
+ T cells under normal growth condition
or serum starvation
To confirm that Vpr-mediated cellular damage would result in
cell death, we transfected HEK 293 cells with GFP vector (control)
or the plasmid encoding Vpr-GFP or Vpr52–96-GFP, and
examined the death rate by flow cytometry. Death rates of Vpr-
GFP and Vpr52–96-GFP expressing cells were significantly higher
(p,0.001) at 48, 72, and 96 hours post-transfection (Fig. 8A). As a
comparison, we infected HEK293 cells with lentiviral vector
carrying Vpr. The death rate of Lenti-Vpr-infected cells, as
observed in Vpr-GFP and Vpr52–96-GFP expressing cells after
transfection, increasing proportionally over time following infec-
tion, were significantly higher (p,0.001) than the control at 48, 72,
and 96 hours post-infection (Fig. 8A, 8B).
We further investigated whether Vpr can cause similar cellular
damage in non-dividing cells under serum starvation. HEK 293
cells were starved for 24 hours, and infected with Vpr-expressing
lentivirus for 72 hours. Our results showed that, compared with
the Vpr-negative control cells, we observed the reduced Mfn2,
increased leakage of MMP and enhanced cell death (p,0.01) in
serum-starved Vpr-expressing cells, with significantly lower impact
(p,0.05 for less MMP loss and p,0.01 for decreased cell death)
than that under normal growth condition (Fig. 8C, 8D and 8E).
Considering that CD4
+ T cells are the primary target of HIV-1,
we further examined the influence of Vpr on Sup T1, a human
CD4
+ T lymphoblast cell line. Similar to that observed in
HEK293 cells, Vpr-expressing lentivirus caused Mfn2 reduction,
MMP loss (p,0.001) and cell death (p,0.001) in SupT1 cells
under both normal growth condition and serum starvation, with
slightly decreased effects (p,0.05 for less cell death) in serum-
starved cells (Fig. 8C, 8D and 8E). It is worth noting that Vpr
effects on MMP loss and cell death were more profound in SupT1
cells than in HEK293 cells.
The effect of Vpr on human primary CD4
+ T cells was further
examined. As observed in CD4
+ SupT1 and HEK293 cells, Vpr-
expressing lentivirus reduced Mfn2 expression and increased the
level of DRP1 in the nucleus, which correlated with MMP leakage
(p,0.001) and cell death (p,0.01) in primary CD4
+ T cells
(Fig. 8F, 8G and 8H).
Enforced expression of Mfn2 and DRP1 relieves Vpr-
induced apoptosis
As noted above that the reduction of Mfn2 protein and the
decreased cytoplasmic distribution of DRP1 were the primary
effects of Vpr, we therefore investigated whether Mfn2 and
DRP1expression may relieve the cell death induced by Vpr. HEK
293 and SupT1 cells were respectively transfected with Mfn2,
DRP1, and Mfn2/DRP1 expression plasmids for 24 hours, and
infected with Vpr-expressing lentivirus for 72 hours. To evaluate
the apoptotic cell death, we further examined the 89 kDa cleavage
fragment of poly(ADP-ribose) polymerase (PARP), an apoptotic
marker [29]. Vpr induced the apoptotic cleavage of PARP
whereas the enforced expression of Mfn2 and DRP1 greatly
reduced PARP cleavage in Vpr-positive HEK 293 cells (Fig. 9A).
Similarly, overexpression of Mfn2 and DRP1 decreased the
cleavage of PARP in Vpr-expressing SupT1 cells (Fig. 9B).
Moreover, the losses of MMP and cell death induced by Vpr were
also alleviated in Mfn2- and DRP1-expressing HEK 293 and
SupT1 cells (Fig. 9C and 9D).
Vpr down-regulated Mfn2 expression via VprBP-DDB1-
CUL4A ubiquitin ligase in a proteasome-dependent
manner
Recent studies indicate that Vpr can act as an adaptor to
interact with CUL4 E3 ubiquitin ligase complex, containing
damaged DNA binding protein1 (DDB1), E3 ubiquitin ligase
scaffold protein cullin 4A (CUL4A), and DDB1-CUL4A–associ-
ated factor 1 DCAF1 (also called VprBP) [30,31], and down-
regulate host cellular protein in a proteasome-dependent manner
[31,32,33]. Because Vpr did not influence the mRNA expression
of Mfn2 (data not shown), we examined whether the reduction of
Mfn2 might be mediated by the VprBP-DDB1-CUL4A ubiquitin
ligase complex. We measured the effect of proteasome inhibitor
MG132 on Vpr-induced Mfn2 reduction to determine if the
reduction of Mfn2 involved proteasomal degradation. After
treatment with MG132, the protein level of Mfn2 and Vpr was
increased in HA-Vpr and Flag-Mfn2 co-expressing cells (Fig. 10A).
Moreover, the Mfn2 expression did not decrease in Lenti-Vpr-
infected cells after MG132 treatment, suggesting that Vpr-induced
reduction on Mfn2 might be mediated through proteasomal
degradation (Fig. 10B).
A co-immunoprecipitation (co-IP) assay was performed on
transfected cell lysates to examine whether Vpr was directly bound
to Mfn2. In the co-IP assay, we found that there was weak
interaction between Vpr and endogenous Mfn2 (Fig. 10C).
However, Vpr was markedly coimmunoprecipitated with Mfn2
Figure 7. Transportation of Vpr protein from the ER/MAM to
the mitochondria as determined by the time-lapse confocal
fluorescence microscopy. A, Confocal fluorescence time-lapse
images of Vpr52–96-GFP and CFP-ER co-expressed HEK293 cells show
the formation of Vpr-containing transport vesicles (green fluorescence)
from the ER/MAM (red fluorescence; yellow fluorescence indicates the
merge of the green and the red fluorescence. Arrows indicate the
region (ER/MAM, yellow fluorescence) where the Vpr52–96-GFP emerges.
Intensity of yellow fluorescence in the ER/MAM decreases following the
appearance of Vpr-containing transport vesicles (green fluorescence,
T=14 s–28 s). B, Fusion of the Vpr-containing transport vesicles (green
fluorescence, Vpr52–96-GFP) into the mitochondria (red fluorescence,
MitoTracker-Red) in real time. As shown in time-lapse series, Vpr-
containing transport vesicle (green fluorescence) approached a
mitochondrion (red fluorescence, T=28 s), and then fused into the
mitochondrion (T=56 s). Arrows indicate Vpr52–96-GFP molecules that
merge into the mitochondrion, and the fusion spot appears as yellow
fluorescence (arrow). Results of the confocal fluorescence microscopy
demonstrate that Vpr is budding off from the ER/MAM and forms within
a spherical vesicle, which moves to the vicinity of the mitochondrion
and then fuse into the organelle.
doi:10.1371/journal.pone.0033657.g007
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+ T cells under normal growth condition or
serum starvation. A, HEK293 cells were transfected with GFP vector the plasmid encoding Vpr-GFP or Vpr52–96-GFP, and harvested at different time
(hours) post-transfection for PI staining. The percentage of dead cells among GFP-expressing cells was determined by flow cytometry. *** (p,0.001)
indicates significantly different from the GFP vector control. B, HEK293 cells were infected with lenti-vector (control) or Lenti-Vpr and harvested at
different time (hours) post-infection for PI staining. The percentage of dead cells was determined by flow cytometry. *** (p,0.001) indicates
significantly different from the control. C, HEK293 and SupT1 cells were grown in 10% FBS or starved for 24 hours, and infected with Vpr-expressing
lentivirus for 48 and 72 hours. The expression of Mfn2 was decreased in serum-starved HEK293 or SupT1 cells. The quantitative expression of Mfn2
was measured by Image J and normalized with the expression of b-actin. C indicates Vpr negative lentiviral control. D, MMP loss was determined
after Vpr-expressing lentivirus infection. Vpr significantly impaired MMP in serum-starved HEK293 and SupT1 cells. E, Vpr expression led to cell death
in serum-starved HEK293 and SupT1 cells. For panels D and E, results are the means 6 S.D. of three independent experiments. * (p,0.05), ** (p,0.01)
and ** (p,0.001) indicate significantly higher than the Vpr negative lentiviral control (Con.). { (p,0.05) and {{ (p,0.01) indicate significantly different
between 10% FBS and serum starvation. F, Human primary CD4
+ T cells were isolated from peripheral blood mononuclear cell (PBMC) and infected
with Vpr-expressing lentivirus for 72 hours. The expression of Mfn2 was decreased and the expression of nuclear DRP1 was increased in human
primary CD4
+ cells. The relative expression levels of Mfn2 and DRP1 were measured by Image J and normalized with the expression of b-actin. G,
MMP loss was determined after Vpr-expressing lentivirus infection. Vpr led to a significant MMP loss in human primary CD4
+ T cells. H, Vpr expression
led to cell death in human primary CD4
+ T cells. For panels G and H, results are the means 6 S.D. of three independent experiments. ** (p,0.01) and
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were transiently presented as a complex in the cells (Fig. 10D). To
explore whether Mfn2 degradation was regulated by Vpr-VprBP-
DDB1-CUL4A ubiquitin complex, we silenced VprBP, DDB1,
and CUL4A, and infected cells with Lenti-Vpr. The result showed
that Mfn2 protein was not decreased in VprBP-, DDB1- and
CUL4A-slienced Lenti-Vpr-infected cells. Interestingly, the band
of ubiquitinated Mfn2 was increased in VprBP
KD, DDB1
KD, and
CUL4A
KD Lenti-Vpr-infected cells, suggesting that Vpr-mediated
Mfn2 reduction was via DDB1-CUL4A-VprBP ligase complex
(Fig. 10E).
Because Vpr-induced Mfn2 reduction would lead to MMP loss,
we measured the percentage of MMP loss in Vpr-expressing cells.
Notably, compared with control cells, MMP loss was reduced in
VprBP
KD-, DDB1
KD-, and CUL4A
KD- cells after Lenti-Vpr
infection, indicating that Vpr targeted Mfn2 to damage mitochon-
dria through interacting with VprBP-DDB1-CUL4A ligase com-
plex (Fig. 10F). In addition to maintaining mitochondria homeo-
stasis, Mfn2 has been shown to inhibit cell proliferation by arresting
cell cycle in the G0/G1 phases [34,35,36]. We transfected the
plasmid encoding FLAG-Mfn2 into Lenti-Vpr-infected cells and
analyzed the cell cycle by flow cytometry. Compared with Lenti-
Vpr-infected cells, which were arrested at G2 phase (G2/G1 ratio:
4.43), enforced expression of Mfn2 indeed relieved G2 arrest (G2/
G1 ratio: 2.52) (Fig. 10G). These results indicate that G2 arrest
activity of Vpr may be attributed in part to its ability to down-
regulated Mfn2 expression via VprBP-DDB1-CUL4A ubiquitin
ligase in a proteasome-dependent manner.
*** (p,0.001) indicate significantly higher than control human primary CD4
+ T cells. Band intensities were calculated using Image J. Relative
intensities are shown at the bottom of each panel.
doi:10.1371/journal.pone.0033657.g008
Figure 9. Enforced expression of Mfn2 and DRP1 relieves Vpr-induced apoptosis. After transient transfection of Mfn2, or DRP1 expression
plasmid for 24 hours, cells were infected with Vpr-expressing lentivirus for 72 hours. A, In contrast to Lenti-Vpr negative (-) HEK293 cells (medium
control and vector control), the 89 kDa cleavage fragment of PARP appeared exclusively in Lenti-Vpr positive (+) HEK293 cells. PARP cleavage was
reduced in Mfn2-, DRP1- and Mfn2/DRP1-overexpressed Lenti-Vpr (+) HEK293 cells. B, PARP cleavage occurred only in Lenti-Vpr (+) SupT1 cells. The
cleavage of PARP was reduced in Mfn2-, DRP1- and Mfn2/DRP1-expressed Lenti-Vpr (+) SupT1 cells. C, Overexpression of Mfn2, DRP1, and Mfn2/DRP1
decreased the percentage of MMP loss in Lenti-Vpr (+) HEK293 and SupT1 cells. D, Overexpression of Mfn2, DRP1, and Mfn2/DRP1 reduced Vpr-
induced apoptosis. Results are the means 6 S.D. of three independent experiments. For panels C and D, { (p,0.05) and {{ (p,0.01) indicate
significantly lower than Lenti-Vpr (+) cells pretreated with mock (medium control) or vector transfection.
doi:10.1371/journal.pone.0033657.g009
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e33657Figure 10. Vpr downregulated Mfn2 expression via VprBP-DDB1-CUL4A ubiquitin ligase complex. A, HEK293 cells were transfected
respectively with plasmids encoding HA-Vpr and Flag-Mfn2 for 32 hours and treated with proteasome inhibitor MG132 (5 mM) for 16 hours. The
expression of Mfn2 was recovered after MG132 treatment. B, HEK293 cells were infected with Lenti-Vpr for 56 hours and treated with proteasome
inhibitor MG132 (5 mM) for 16 hours. The expression of Mfn2 was not decreased after MG132 treatment. C, HEK293 cells were transfected with the
plasmid encoding HA-Vpr and harvested after 48 hrs. Cell lysates were immunoprecipitated with anti-HA antibody, and detected by Western blotting.
D, HEK293 cells were transfected respectively with plasmids encoding HA-Vpr and Flag-Mfn2 for 32 hours and treated with MG132 (5 mM) for
16 hours. Cell lysates were immunoprecipitated with anti-HA antibodies, and the coimmunoprecipitated proteins were detected by Western blotting.
* indicates the ubiquitinated Mfn2. E, HEK293 cells were silenced by shRNA against DDB1, VprBP or CUL4A, and infected with lentivirus carrying Vpr
for 72 hours. The ubiquitinated Mfn2 was detected in VprBP
KD, DDB1
KD, CUL4A
KD cells. Moreover, Vpr infection did not decrease Mfn2 expression in
VprBP
KD, DDB1
KD, CUL4A
KD cells. * indicates the ubiquitinated Mfn2. F, The MMP loss was determined by flow cytometry after Lenti-Vpr infection.
Knockdown of DDB1, VprBP and CUL4A reduced the percentage of MMP loss after Lenti-Vpr infection. G, HEK293 cells were infected with Lenti-Vpr
for 24 hours and transfected with the plasmid encoding FLAG-Mfn2 for 48 hours. Cells were harvested and analyzed by Western blotting and flow
cytometry. Band intensities were calculated using Image J. Relative intensities are shown at the bottom of each panel.
doi:10.1371/journal.pone.0033657.g010
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The present study demonstrated that the major cytotoxic effect
of HIV-1 Vpr might be damage to the mitochondria. This could
be caused by the integration of C-terminal TMD on the
mitochondrial outer membrane (MOM) reducing mitochondrial
membrane potential (MMP), thereby leading to fragmentation of
the mitochondria and swelling of the cristae. Moreover, Vpr
markedly reduced the protein levels of Mfn2 via VprBP-DDB1-
CUL4A ubiquitin ligase complex, in which gene deficiency is
closely associated with mitochondrial dysfunction and cellular
apoptosis.
An elegant study by Jacotot et al. [37] showed that exogenously
added recombinant Vpr (rVpr) induced the rapid dissipation of
mitochondrial membrane potential (MMP), as well as the release
of apoptogenic proteins, such as cytochrome c and apoptosis
inducing factor (AIF), from the mitochondria. They further found
that the influence of rVpr was via interaction with permeability
transition pore complex (PTPC) or its components, e.g., adenine
nucleotide translocator (ANT) and voltage-dependent anion
channel (VDAC), facilitating proapoptotic Bax-related membrane
permeabilization. On the other hand, anti-apoptotic Bcl-2 and
inhibitory reagents of PTPC, e.g., cyclosporine A and bongkrekic
acid, inhibit the cytotoxic effects of Vpr on nuclear apoptosis.
However, a study by Andersen et al. [12] showed that the silencing
of ANT expression alone did not affect Vpr-associated apoptosis.
On the contrary, they showed that the toxic effect of Vpr was on
the MOM, probably on Bax-targeting proteins [38]. Interestingly,
the presence of a potential C-terminal TMD suggests that Vpr is a
tail-anchored protein, which could be located on the ER and the
MOM [11,14,16,39,40,41]. Our results of protease protection
support their findings in which Vpr is an integral protein with the
N-terminus facing the cytoplasm. A short 20 amino-acid C-
terminal stretch in the ER lumen or mitochondrial intermembra-
nous space, containing seven arginine residues, further implies that
this arginine-rich region may interact specifically with C-terminal
aspartates of VDAC, thereby interfering with its activity [42].
However, the role of VDAC in Vpr-related cell death remains to
be determined.
Like Vpr, VDAC was also detected on both the mitochondria
and the ER, particularly in areas resembling MAM [43], contact
sites between the ER and mitochondria at which Mfn2 on both
organelles tethered them together to coordinate Ca
2+ flow [44]. It
is possible that Vpr influences the function of VDAC on Ca
2+
homeostasis in both organelles. In fact, the Bcl-2 family proteins,
e.g., antiapoptotic Bcl-2, or proapoptotic Bax and Bak, the
effectors of Vpr were also detected on both organelles modulating
inter-organelle Ca
2+ exchange as well as rheostatically regulating
the initiation of apoptosis [45]. The critical issue is whether the
newly synthesized proteins simultaneously target both organelles
or if they are synthesized in one organelle and subsequently
transported to the others. In this study, we have demonstrated by
time-lapse confocal fluorescence microscopy that transport of Vpr
protein is from the ER via MAM to the mitochondria. We noticed
a faster rate of Vpr formation from the MAM than that of
transport vesicle fusion into the mitochondrion. This implicates
that the two events could be regulated by different enzymes, such
as DRP1 and Mfn2.
Several studies have characterized the function of Vpr fusion
proteins. An earlier study in 1995 by Di Marzio et al. [46] showed
that N-terminal HA tagged Vpr (HA-Vpr) retained G2 arrest
activity whereas C-terminal HA and luciferase (either N- or C-
terminal end) tagged Vpr fusion proteins lost cell cycle arrest
activity. Later on in 2003, Waldhuber et al. [47] demonstrated
that, compared with the wild type Vpr or N-terminal His-tagged
Vpr, Vpr fused with N-terminal GFP (Vpr-GFP) or C-terminal
GFP (Vpr-GFP) caused an earlier (24 hours) yet transient (not
sustained to 72 hours) G2 arrest activity. Both GFP-Vpr and Vpr-
GFP, nevertheless, could induce apoptosis as efficient as wild type
Vpr. They suggest that G2 arrest activity of Vpr is separable from
its activity to induce apoptosis [47]. Similarly, Anderson et al. [12]
observed a defective G2 arrest activity despite of an intact
apoptosis-inducing activity in Vpr-GFP. In contrast, another study
by Muthumani et al. [48] showed that Vpr-GFP is fully functional
as the wild type Vpr, with equivalent activities in G2 arrest
(48 hours after transfection), nuclear translocation, replication
kinetic, and infectivity for CD4
+ T cells, macrophages, and
dendritic cells. In our study, we observed a normal G2 arrest
activity in Vpr52–96-GFP expressing cells, with a similar G2/G1
ratio as Lenti-Vpr infected cells (1.55 vs. 1.42 at 48 hours). On the
other hand, the lower G2/G1 ratio of HA-Vpr (1.09) and Vpr-
GFP (0.71) expressing cells could be due to the lower transfection
rate (as opposed to the higher infection rate) along with the lower
G2 arrest activity. Overall, the disparity in G2 arrest activity
among Vpr fusion proteins [12,46,47,48] reflects that this
functional domain is sensitive to modification with variability.
GFP fusion of Vpr, in particular, may (partially or completely) or
may not compromised G2 arrest activity, possibly depending on
the conformation of each individual construct [12,48]. In this
study, both Vpr52–96-GFP (comparable activity) and Vpr-GFP
(lower activity) were active in causing G2 arrest, and showed
comparable ability as Lenti-Vpr to lead to Mfn2 reduction,
increase in nuclear DRP1, MMP loss and cell death.
An elegant study by Borgne-Sanchez et al. [49] has shown that
the recombinant Vpr activates depolarization of MMP in isolated
mitochondria. In intact cells, rVpr induces bulging in some
organelles in addition to the fragmentation of the mitochondria
and abrasion of the MOM. Although considerable work has been
focused on endocytosis, some bulging organelles did not match
with endocytotic markers and the essence of these structures has
not been characterized further. Our data suggests that the effects
of Vpr on mitochondria could be caused by a Vpr-related
reduction in Mfn2, a GTPase which is essential for the fusion and
tethering of membranes [50,51]. The loss of functional Mfn2
would certainly reduce the frequency of fusion among mitochon-
dria [26,27,28,52,53] as well as that between transport vesicles and
mitochondria. The later events could causally lead to a shortage in
phospholipid supply from the ER/MAM to mitochondria,
resulting in abrasion of the MOM [22] and depolarization of
MMP.
Dynamin-related protein 1 (DRP1) is also required for
mitochondrial protein transport [22]. The loss of functional
DRP1 would interrupt the formation and budding-off of transport
vesicles from the MAM, leading to accumulation of cargo proteins
in MAM, and appearing as bulging cytostructures in confocal
fluorescence microscopic images. Interestingly, Vpr, in particular
Vpr52–96, induced organelle bulging as well, suggesting that Vpr
could influence DRP1 activity. Overlapping Vpr images with the
MAM marker, phosphatidylserine synthase 1 (PSS1), in bulging
areas support such a concept. Unlike Mfn2, Vpr did not reduce
total protein levels of DRP1. Our previous study showed that cell
stress could increase nuclear levels of DRP1 [54]. Because DRP1
contains DNA binding motifs, it is possible that DRP1 is
translocated to the nucleus to protect genomic DNA when cells
have been exposed to the genotoxic stress, e.g., HIV-1 replication,
which requires the Vpr-associated formation of pre-integration
complex [55,56]. Nuclear translocation of DRP1 could then
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cellular responses.
Our results indicated that Vpr reduced the expression of Mfn2,
enhanced MMP loss and led to cell death in both cycling cells and
serum-starved non-dividing cells, with a decreased impact on
serum-starved cells. Overexpression of Mfn2 and DRP1 signifi-
cantly decreased the loss of MMP and reduced apoptotic cell death
caused by Vpr. These results show that reduction of Mfn2 and
nuclear translocation of DRP1, being the marked effects of Vpr-
mediated cellular damage, can be rescued, in part, by the enforced
expression of Mfn2 and DRP1. However, the fact that Vpr-
induced MMP loss and cell death are only partly reduced by Mfn2
and DRP1 suggests that more factors may be involved in the
process.
Previous studies have shown that Vpr could interact with
CUL4A ubiquitin complex to degrade proteins, such as UNG and
SMUG [32,33]. On the other hand, the stability of Mfn2 has been
suggested to be regulated by the ubiquitin/proteasome system
[57]. In our study, we showed here that Vpr downregulated Mfn2
via VprBP- DDB1-CUL4A ubiquitin ligase complex in a
proteasome-dependent manner. However, our study does not rule
out that there could be other factors, such as Parkin and PINK1,
participating in Vpr-induced Mfn2 reduction [58]. CUL4A
ubiquitin complex has been shown to be involved in the Vpr-
mediated G2 arrest [59,60,61,62]. Other than functioning in
mitochondrial fusion, Mfn2 can act as a cell proliferation
suppressor to inhibit cell cycle transition from the G1 to S phase
[34,35]. In this study, we showed that enforced expression of Mfn2
relieved G2 arrest in Lenti-Vpr-infected cells. Taken altogether, by
reducing the expression of Mfn2 via VprBP-DDB1-CUL4A
ubiquitin ligase complex, Vpr may allow G1 cells to proceed
through S phase and finally stop at G2 phase due to some other
mechanism. For example, Li et al. [63] has suggested that Vpr
mediates G2 arrest through an S phase dependent mechanism
which involves Chk1 activation. Mfn2 reduction to facilitate an S
phase may represent an earlier event triggered by Vpr, which is
required for later events to lead to G2 arrest.
Vpr lacks the classical mitochondrial targeting sequence [16]
and our data proves that the transport of Vpr to mitochondria is
independent of TOM complex. Furthermore, we show that Vpr
protein is transported from the ER/MAM to the mitochondria.
Using organelle fractionation and Western blotting to study the
intracellular distribution of cytomegalovirus UL37 proteins,
Bozidis et al. [64] have demonstrated that UL37 is detected in
the microsomes/ER, MAM and mitochondria. Using deletion
mutants and confocal fluorescence microscopy, Williamson and
Colberg-Poley [65] have further shown that the predominant
UL37 isoforms, pUL37x1 (also known as vMIA) is first detected in
the ER, and then successively in MAM, and mitochondria.
Recently, we demonstrated that apoptosis-inducing factor (AIF), a
mitochondrial protein located in the intermembranous space of
mitochondria, was transported into mitochondria via ER and
MAM [66]. These studies not only correspond well with our
current data, but also suggest that protein transport from the ER,
via the MAM to the mitochondria could be a general
phenomenon for some endogenous as well as exogenous
polypeptides. It should be noted, nevertheless, that other
explanations are possible. For instance, nuclear Vpr could directly
induce DNA damage while cytoplasmic Vpr interacts with anti-
apoptotic mitochondrial protein HAX1 (HS1-associated protein
X-1) [67], decreasing the function of high Ca
2+ affinity SERCA2a
(sarco/endoplasmic reticulum Ca
2+ transport ATPase 2a) for Ca
2+
influx to the ER [68]. It is conceivable that Vpr could collaborate
with HIV-1 Nef protein to alter the activities of inositol-1,4,5-
triphosphate receptor (PI3R) in Ca
2+ efflux from the ER [69]. On
the other hand, HIV-1 protease could directly degrade retinoic
acid-inducible gene 1 (RIG-I) and inhibit the initiation of
mitochondrial antiviral signaling (MAVS) and the subsequent
activation of interferon regulatory factor 3 (IRF3) [70,71]. Vpr
could also influence the transport of MAVS to the mitochondria.
In this manner, collaboration among viral proteins could
simultaneously increase cytoplasmic Ca
2+ level, thereby facilitating
viral production, preventing innate immunity and inducing cell
death.
Because only a small amount of Vpr is incorporated into virus
particles, virion-associated Vpr may not be sufficient to induce
dramatic mitochondrial deformation and lead to apoptosis. In fact,
Vpr that is expressed in low level may have anti-apoptotic activity
[72,73]. On the other hand, previous studies have shown that Vpr
led to apoptosis over 48 hours of infection by adenovirus-based
vector [3,74], revealing the profound effect of Vpr due to post-
infection gene expression. Similarly, our results showed that loss of
MMP and increased apoptotic cell death were significant over
24 hours of infection, suggesting that Vpr-induced apoptosis is
resulted from Vpr gene expression after HIV-1 reverse transcription.
In conclusion, we show that Vpr is not directly transported to
the mitochondria. Instead, it is synthesized in the ER, and
transported to the mitochondria via MAM and transport vesicles.
This process requires at least three critical proteins, including
Mfn2, DRP1, and ATAD3A. Moreover, Vpr reduces the
expression of the Mfn2, resulting in abrasion of the MOM,
leading to fragmentation of the mitochondria, swelling of the
cristae, loss of MMP, release of apoptogenic proteins, and the
initiation of cell death.
Materials and Methods
Ethics statement
Antibodies were raised in mice in strict accordance with the
Guidebook for the Care and Use of Laboratory Animals of the
Council of Agriculture, Executive Yuan, Taiwan. The specific
details of our protocol (IACUC approval number: 98–89) were
reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC), National Chung Hsing University (IACUC
of NCHU), Taiwan. All efforts were made to minimize suffering
and to reduce the number of mice.
Human peripheral blood mononuclear cell were obtained from
healthy volunteers with informed consent. The protocol (IRB
approval 100-IRB-07) was reviewed and approved by the
institutional review board (IRB), National Chung Hsing University
(IRB of NCHU), Taiwan.
Expression plasmids and gene construction
Plasmids pAS1B-HA-Vpr and pEGFP-N1-Vpr were obtained
from Dr. S. Benichou [75]. The pcDNA3.1-Vpr was obtained
from Dr. B. E. Sawaya [6]. The MAM marker construct, FH-PSS-
1, was provided by Dr. O. Kuge [76]. The ER marker, DsRed-
ER, was from Dr. D. J. Snyders. Plasmids pcDNA3.1-Flag-Mfn2
and pcDNA3.1-DRP1 were obtained from Dr. R. J. Youle. The
mitochondrial marker, DsRed-Mito was provided by Dr. F.
Peruzzi. To generate the truncated mutant of Vpr, we performed
PCR using Vpr-GFP plasmid as the template. The primer
sequences for the truncated Vpr was as follows: 59-CTACTCGA-
GATGACTTGG GCAGGAGTGG AA -39 (nts 5261–5279, Xho
I site is underlined and the initiation codon is in bald-phase letters,
NC_001802); and 59-GCAAAGCTTGGATCTACTGGCTC-
CATTTCT-39 (nts 5373–5393, Hind III site is underlined). The
amplified DNA fragment corresponded to the C-terminal
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digested with Xho I and Hind III, and the small DNA fragment was
removed using the QIAquick PCR purification kit (QIAGEN,
Duesseldorf, Germany). Vpr-specific inserts were subcloned into
the pEGFP-N1 vector. For infection, full-length Vpr was amplified
and subcloned into pLKO-AS3w vector (Academia Sinica, Taipei,
Taiwan). The pLKO.1-lentivirus constructs carrying small hairpin
RNA (shRNA) against Tom20, Tom22, Tom40, DRP1, DDB1,
VprBP, CUL4A and Mfn2, were obtained from the National
RNAi Core Facility, Academia Sinica, Taipei, Taiwan.
Cell culture and transient transfections
Human embryonic kidney cell lines HEK293 and 293T
(HEK293 stably expressing the SV40 large T-antigen) were
obtained from ATCC (Manassas, VA, USA) and grown in
Dulbecco modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 4 mM glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin. The cells were grown to
80% confluence on the day of transfection. The pEGFP-N1-Vpr
encoding Vpr-GFP was transfected into target cells using jetPEI
cationic polymer transfection reagent (Polyplus-transfection Inc.,
Illkirch, France).
Human CD4
+ T lymphoblast cell line SupT1 was obtained
from ATCC and grown in RPMI1640 medium supplemented
with 10% FBS, 4 mM glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin. Transient transfections of SupT1 cells
were performed by using jetPEI transfection reagent. Briefly,
2.5610
6 cells were transfected with 4 mg of Mfn2 or DRP1
expression plasmids. After 24 hrs of transfection, the medium was
replaced with medium containing Vpr lentiviral supernatant to
carry out spinoculation [77].
Peripheral blood mononuclear cells were obtained from healthy
donors, and CD4
+ lymphocytes were purified using anti-CD4
magnetic beads (Dynal, Invitrogen, California, USA) according to
the manufacturer’s instructions. Primary CD4
+ T cells were
cultured in complete RPMI and infected with lentiviral superna-
tant carrying Vpr by centrifugal inoculation (spinoculation) as
described previously [77]. After 72 hours, CD4
+ T lymphocytes
were harvested and analyzed.
Lentivirus production and infection
Lentiviral vector carrying shRNA or full-length Vpr insert was
prepared using a three-plasmid transfection method. Briefly, the
pMD.G containing vesicular stomatitis virus glycoprotein, and
pCMV-D 8.91carrying HIV-based packaging plasmid were co-
transfected with lentiviral vector (control) or with the shRNA-, or
Vpr-expressing lentiviral vector into 293T cells. The medium was
changed to fresh DMEM containing 10 mg/ml BSA 24 hours
post-transfection. The supernatant containing lentivirus was
collected at 48 hour and 72 hour post-transfection, respectively.
To infect HEK293 cells, lentiviral supernatant was added directly
to cells in the presence of 8 mg/ml polybrene. SupT1 cells were
infected with lentivirus by centrifugal inoculation (spinoculation) as
described previously [77], and the cells were washed five times
with medium. Following infection, the cells were selected using
1 mg/ml puromycin.
Production of recombinant Vpr protein and antibody
Recombinant Vpr protein was expressed from the pGEX-4T-
Vpr plasmid carrying GST protein at the N-terminus. GST-Vpr
fusion protein was extracted and purified using Glutathione
Sepharose 4B (GE Healthcare, Amersham, UK), and eluted with
10 mM reduced glutathione. Affinity-purified GST-Vpr was used
to immunize BALB/c mice and the specificity of antibodies was
determined by Western blotting. Monoclonal antibodies were
produced using a hybridoma technique, and Vpr-specific
antibodies were screened using ELISA and Western blotting
methods as described previously [78].
Subcellular fractionation
HEK293 cells transfected with the plasmid encoding Vpr-GFP
were resuspended in sucrose homogenization medium (0.25 M
sucrose, 10 mM HEPES, pH 7.4) containing protease inhibitors
(Roche, Basel Schweiz, Switzerland), incubated on ice for 10 min,
and subjected to glass Dounce homogenizer (Wheaton, Illinois,
USA). Following the removal of the nuclei and unbroken cells
through two rounds of centrifugation at 1,0006g for 10 min, the
crude mitochondrial fraction was pelleted by centrifugation at
10,5006g for 10 min. The supernatant was a cytosolic fraction. The
cytosolic and mitochondrial fractions were normalized for cell
equivalents, and the distribution of Vpr- GFP fusion protein and
marker proteins was assessed by Western blotting as described [78].
Fractionation of MAM, mitochondria, and microsomes
MAM, mitochondria, and microsomes were isolated from Vpr-
GFP expressing cells as previously described [64,79,80,81]. Briefly,
after Dounce and removal of the nuclei and unbroken cells, the
supernatant was centrifuged at 10,5006g for 10 min to separate
the crude microsomal fraction (containing microsomes and
cytosol) from the crude mitochondrial fraction (containing MAM
and mitochondria). The crude microsomal fraction (supernatant)
was subjected to an ultracentrifugation at 100,0006g in a
Beckman SW41 rotor for 60 min at 4uC to pellet the microsomes
and ER (LM fraction), while the supernatant contained only
cytosol. The crude mitochondrial fraction (pellet) was resuspended
in 300 ml of ice-cold mannitol buffer A (0.25 M mannitol, 0.5 mM
EGTA, 5 mM HEPES, pH 7.4) and layered on top of 10 ml of a
30% Percoll suspension in mannitol buffer B (0.225 M mannitol,
1 mM EGTA, 25 mM HEPES, pH 7.4). Mitochondria and
MAM fractions were separated in self-generating Percoll gradients
by ultracentrifugation at 95,0006g in a Beckman SW41 rotor for
65 min at 4uC. The mitochondrial fraction was diluted five times
in mannitol buffer B and subjected to centrifugation at 6,3006g for
10 min at 4uC to pellet the purified mitochondria. The MAM
fraction was briefly centrifuged at 6,3006g for 10 min at 4uCt o
remove the mitochondria, and the supernatant was further
centrifuged at 100,0006g in a Beckman SW41 rotor for 30 min
at 4uC to obtain the purified MAM (pellet). All fractions were
resuspended in sucrose homogenization medium and analyzed by
Western blotting.
Protease accessibility assays
Crude mitochondrial fractions obtained from HA-Vpr or Vpr-
GFP expressing cells were resuspended in SM buffer (0.25 M
sucrose, 10 mM MOPS-KOH, pH 7.2) or SMTX-1 buffer (SM
buffer containing 0.1% Triton X-100). Equal quantities of
mitochondria were divided into aliquots and treated with protease
as previously described [82,83]. Briefly, proteinase K was added to
final concentrations of 10, 20, 50 or 100 mg/ml. The samples were
incubated on ice for 15 or 30 min. The reaction was stopped by
the addition of 4 mM phenylmethylsulfonyl fluoride. The proteins
were precipitated using acetone and centrifuged at 12,000 rpm for
30 min. The precipitated proteins were analyzed by Western
blotting with anti-GFP antibodies (1:3,000, Abcam, Cambridge,
UK) or with antibodies to COX IV, a mitochondrial marker
protein. The same procedure was used for trypsin digestion
(30 mg/ml) and the proteolysis was stopped with cocktail protease
inhibitors (Roche, Basel Schweiz, Swiss).
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LM fractions, containing enriched microsomes, and crude
mitochondrial fractions were resuspended in freshly prepared ice-
cold 0.1 M sodium carbonate (pH 11.5) at a final concentration of
500 mg of protein per ml of sodium carbonate. After incubation on
ice for 20 min, the extracts were centrifuged at 130,0006g for
60 min. The pellet was solubilized in SDS sample buffer. The
supernatant proteins were precipitated using acetone and
centrifugation, and then solubilized in SDS sample buffer prior
to Western blot analysis.
Western blot analysis and co-immunoprecipitation
A total of 30 mg of total lysates or 10 mg of subcellular fractions
were separated using SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and analyzed by Western blotting. Blots were
incubated with the respective primary antibodies, such as rabbit
anti-GFP (1:3,000, Abcam, Cambridge, UK), rabbit anti-PARP
(1:3,000, Cell signaling, Massachusetts, USA), rabbit anti-CUL4A
(1:1,000, Cell signaling, Massachusetts, USA), rabbit anti-DDB1
(1:1,000, Cell signaling, Massachusetts, USA), rabbit anti-VprBP
(1:1,000, Novus Biologicals, Colorado, USA), mouse anti-HA tag
(1:1,000, Santa Cruz Biotechnology, California, USA), goat anti-
FACL4 (1:100, Santa Cruz Biotechnology, California, USA),
mouse anti-calnexin (1:3000, Abcam, Cambridge, UK) or mouse
anti-COX IV (1:1000, Invitrogen, California, USA). Protein
signals were detected using horseradish peroxidase-conjugated
secondary antibodies (1:10,000, GE Healthcare, Amersham, UK)
and Immobilon Western Chemiluminescent HRP Substrate
(Millipore, Massachusetts, USA). The digital images were
processed in Adobe Photoshop 7.0. Each blot was stripped using
Restore Western Blot Stripping Buffer (Pierce, Illinois, USA) and
incubated with other antibodies. The results were analyzed and
quantified by Image J software (NIH, MD, USA).
Measurement of mitochondrial membrane potential
Cells were stained with cell permeable, green fluorescent, lipophilic
dye 3, 30-dihexyloxacarbocyanine iodide (DiOC6; Invitrogen,
California, USA) as described [84,85]. The dye was freshly prepared
(50 nM in PBS) and added to the suspension (10
6 cells/ml). After
20 min of incubation at 37uC in the dark, the samples were analyzed
using a flow cytometer (FACS Calibur, BD, California, USA).
Indirect immunofluorescence and confocal microscopy
Cells, which were co-transfected with organelle specific
plasmids, DsRed2-ER, DsRed-Mito, FH-hPSS1 and Vpr-GFP
for 24 hours, were reseeded onto slides. After 48 hours, the
transfected cells were fixed with 4% paraformaldehyde for 15 min
at room temperature and analyzed by confocal microscopy. FH-
hPSS1 expressing cells were permeabilized with 0.1% Triton X-
100 for 15 min at room temperature prior to staining with mouse
anti-HA tag (1:500, Santa Cruz Biotechnology, California, USA),
and Alexa 546 rabbit anti-mouse IgG secondary antibodies (1:300,
Invitrogen, California, USA). Imaging was captured by using a
Laser Scanning Confocal Microscope, LSM510 (Carl Zeiss, New
York, USA). Images were processed using Adobe Photoshop. For
the real time observation, time-lapse confocal fluorescence
microscopy was employed with an Olympus FV-1000 confocal
microscope (Tokyo, Japan) and the images were analyzed by using
FV10-ASW 3.0 software (Tokyo, Japan).
Electron microscopy
Cells were fixed in situ on culture dishes with 2.5%
glutaraldehyde (Sigma, Missouri, USA) in 100 mM phosphate
buffer (PB) (pH 7.2) at 4uC overnight. Cells were washed with PB
before post-fixation with 1% osmium tetroxide in PB for 1 hour.
After washing with distilled water, the cells were suspended in 2%
agarose, and the agarose blocks were trimmed and dehydrated in a
serial dilution of ethanol for 15 min each. The blocks were further
dehydrated three time using 100% ethanol for 15 min each, and
infiltrated with 100% ethanol/LR white (1:1) mixture overnight.
The blocks were changed to LR white (Agar Scientific Ltd., Essex,
UK) for continuous infiltration at 4uC for 24 hours before being
transferred to a capsule filled with LR white. LR white was
polymerized and solidified at 60uC for 48 hours. The resin blocks
were trimmed and cut using ultramicrotome (Leica Ultracut R,
Vienna, Austria). Thin sections were transferred to 200 mesh
copper grids, and stained with 2% uranyl acetate for 15 min, and
2.66% lead citrate (pH 12.0) for 15 min prior to observation with
a JEM1400 electron microscope (JEOL USA, Inc., Massachusetts,
USA) at 100–120 kV.
Post-embedding immunogold procedure for electron
microscopy
Vpr-GFP expressing cells were fixed using 4% paraformaldehyde
and 0.1%glutaraldehyde inPBSbufferat4uC for 18 hoursand then
permeabilized with 0.2% TritonX-100 in PBS for 1 hour. After
being washed with PBS 3 times, the cells were embedded in 2%
agarose gel and the block was cut into several pieces prior to
dehydration. Following dehydration in a series of ethanol of
escalated concentration, samples were embedded in LR White
resin. Thin sections were cut using ultramicrotome and transferred
to nickel grids. The non-specific binding sites on the thin sections
were blocked with 50 mM glycine and 1% BSA in PBS for 15 min.
The sections were incubated with rabbit anti-GFP polycolonal
antibodies(1:100)ormouseanti-Vprmonoclonalantibodies(1:20)in
incubation buffer (0.1% BSA and 15 mM NaN3 in PBS) for
18 hours at 4uC, respectively. The antibodies were removed by
washing the grids with incubation buffer 6 times and the grids were
further incubated with 15 nm gold-conjugated secondary antibodies
(1:50) (Aurion, Wageningen, Netherlands). Following removal of the
non-binding antibodies through repeated washing of the grids with
incubation buffer, the sections were post-fixed with 2% glutaralde-
hyde in PBS for 5 min and stained with uranyl acetate and lead
citrate prior to observation with a JEM1400 electron microscope.
Flow cytometric analysis of dead cells
HEK 293 cells were transfected with GFP vector, or the plasmid
encoding Vpr-GFP or Vpr52–96-GFP, and harvested at different
time (hrs) post-transfection. Cells were stained with propidium
iodide (PI) for 5 to 10 min. The percentage of dead cells (positive
stain for PI) among GFP-expressing cells was determined by using
a flow cytometer (FACS Calibur, BD, California, USA).
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